Get the Stockscreener App
22.23
1.20%
-0.27
Roivant Sciences Ltd stock is traded at $22.23, with a volume of 4.27M.
It is down -1.20% in the last 24 hours and up +6.52% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$22.50
Open:
$22.31
24h Volume:
4.27M
Relative Volume:
0.53
Market Cap:
$15.46B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
3.9345
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-0.80%
1M Performance:
+6.52%
6M Performance:
+91.64%
1Y Performance:
+85.25%
1-Day Range:
$22.08
$22.41
1-Week Range:
$22.08
$22.76
52-Week Range:
$8.73
$23.47
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
22.23 | 15.65B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Capricorn Fund Managers Ltd Buys New Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Insider Confidence In December 2025's Leading Growth Companies - Yahoo! Finance Canada
Reassessing Roivant Sciences (ROIV) Valuation After Pipeline Progress, NDA Timelines and Genevant Litigation Updates - simplywall.st
Voya Investment Management LLC Grows Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Is Roivant Sciences Ltd stock positioned for digital transformationGap Down & High Conviction Trade Alerts - moha.gov.vn
What margin trends mean for Roivant Sciences Ltd. stockFibonacci Extensions & Fast Profit Trading Tips - bollywoodhelpline.com
Ramaswamy-Backed Ambros Launches with $125M - Orange County Business Journal
Roivant Sciences president Sukhatme sells $619k in shares By Investing.com - Investing.com Australia
Roivant Sciences president Sukhatme sells $619k in shares - Investing.com UK
How Investors May Respond To Roivant Sciences (ROIV) Accelerating Brepocitinib Timelines And Patent Litigation - simplywall.st
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock - MSN
Why Roivant Sciences Ltd. stock is in analyst buy zone2025 Fundamental Recap & Reliable Entry Point Trade Alerts - Улправда
US Market Recap: What margin trends mean for Roivant Sciences Ltd stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
Sell Signal: Will Roivant Sciences Ltd stock maintain momentum in 2025Weekly Stock Report & Pattern Based Trade Signal System - moha.gov.vn
Why Roivant Sciences Ltd. stock could be next big winner2025 Trading Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Can Roivant Sciences Ltd. stock maintain operating marginsJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
How Roivant Sciences Ltd. (87S) stock reacts to fiscal policiesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - Улправда
Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 26,831 Shares - MarketBeat
Pres Sukhatme Sells 26,831 ($619.5K) Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
Can Roivant Sciences Ltd. stock double in next 5 yearsWeekly Market Summary & Daily Technical Stock Forecast Reports - ulpravda.ru
Can Roivant Sciences Ltd. stock outperform in 2025 bull marketMarket Activity Summary & High Conviction Buy Zone Alerts - DonanımHaber
Why Roivant Sciences Ltd. stock remains undervaluedVolume Spike & Consistent Return Strategy Ideas - Bölüm Sonu Canavarı
Will Roivant Sciences Ltd. stock maintain momentum in 2025Weekly Stock Analysis & Long-Term Growth Plans - DonanımHaber
Roivant Sciences Insider Sold Shares Worth $39,065,213, According to a Recent SEC Filing - marketscreener.com
Published on: 2025-12-19 09:31:09 - ulpravda.ru
Will Roivant Sciences Ltd. stock deliver shareholder valueQuarterly Trade Report & Long-Term Safe Return Strategies - Улправда
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 777,332 Shares - MarketBeat
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 917,282 Shares of Stock - MarketBeat
Roivant Sciences (ROIV) director discloses indirect sales of common shares - Stock Titan
Owner QVT Financial LP Sells 1,694,614 ($39.1M) Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
Why Roivant Sciences Ltd. stock remains resilientJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Why analysts remain bullish on Roivant Sciences Ltd. stock2025 Analyst Calls & Accurate Entry and Exit Point Alerts - Улправда
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Published on: 2025-12-18 16:03:55 - Улправда
Roivant Sciences Insider Sold Shares Worth $37,723,200, According to a Recent SEC Filing - marketscreener.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - The Motley Fool
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 1,740,000 Shares of Stock - MarketBeat
Pres Sukhatme Files To Sell 26,831 Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
Valeo Financial Advisors LLC Purchases New Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighShould You Buy? - MarketBeat
Roivant Sciences (ROIV): Reassessing Valuation After Bullish Pipeline and Patent Milestone Updates - simplywall.st
Leerink Partners Maintains Roivant Sciences (ROIV) Outperform Recommendation - Nasdaq
Roivant Sciences stock hits all-time high at 22.45 USD By Investing.com - Investing.com Australia
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Major Shareholder Sells $16,752,432.88 in Stock - MarketBeat
Roivant Sciences (ROIV): Ramaswamy Vivek sells $67.9 million in shares By Investing.com - Investing.com South Africa
Roivant Sciences (ROIV): Ramaswamy Vivek sells $67.9 million in shares - Investing.com
Owner Ramaswamy Sells 3,103,745 ($67.9M) Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
CEO Gline Files To Sell 1,740,000 Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402Has The Bull Case Changed? - Yahoo! Finance Canada
Roivant Sciences (NASDAQ:ROIV) Given New $33.00 Price Target at The Goldman Sachs Group - MarketBeat
Roivant Sciences stock price target raised to $26 from $23 at H.C. Wainwright - Investing.com Australia
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):